SNCA and Parkinson disease: Another class of drugs has been explored for PD management is histone deacetylase 6 (HDAC6) inhibitors such as such as CAY10603 and Tubastatin A which enhance the α-synuclein aggregates clearance to mitigate neurodegeneration17,62.